Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies

European Journal of Neurology

Volumn 19, Issue 6, 2012, Pages 827-833

  Falip, M ^a   Carreno M ^b   Miro J ^a   Saiz, A ^b   Villanueva, V ^c   Quilez A ^d   Molins, A ^e   Barcelo I ^f   Sierra, A ^b   Graus, F ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Autoimmune epilepsy; Glutamic acid decarboxylase antibodies; Limbic encephalitis; Temporal lobe epilepsy

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; THYROID ANTIBODY;

ADULT; ADULT DISEASE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMORBIDITY; FEBRILE CONVULSION; FEMALE; HIPPOCAMPAL SCLEROSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEMORY DISORDER; MOOD DISORDER; ONSET AGE; PRIORITY JOURNAL; SEROPREVALENCE; TEMPORAL LOBE EPILEPSY;

ADULT; ANTIBODIES; EPILEPSY, TEMPORAL LOBE; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOMODULATION; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84860919278     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03609.x     Document Type: Article

References (24)

1. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
2. Jarius S, Stich O, Speck J, et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol 2010; 229: 219-224.
3. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65: 1730-1736.
4. Peltola J, Kulmala P, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55: 46-50.
5. Giometto B, Nicolao P, Macucci M, et al. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 1998; 352: 457.
6. Sokol DK, McIntyre JA, Wagenknecht DR, et al. Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology 2004; 62: 517-518.
7. Malter M, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67: 470-478.
8. Janszky J, Janszky I, Ebner A. Age at onset in mesial temporal lobe epilepsy with a history of febrile seizures. Neurology 2004; 63: 1296-1298.
9. Saiz A, Arpa J, Sagasta A, et al. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology 1997; 49: 1026-1030.
10. Ances BM, Vitaliani R, Taylor RA, et al. Treatment responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005; 128: 1764-1777.
11. Errichiello L, Perruolo G, Pascarella A, et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: a study on 233 patients. J Neuroimmunol 2009; 25: 120-123.
12. Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010; 51: 760-767.
13. Mazzi G, Roia DD, Cruciatti B, Matà S, Catapano R. Plasma exchange for anti-GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci 2008; 39: 229-233.
14. Blanc F, Ruppert E, Kleitz C, et al. Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality? J Neurol Sci 2009; 287: 69-71.
15. Ohara K, Osawa M, Takeuchi M, et al. Stiff-person syndrome with elevated anti-Epstein-Barr virus antibody. Rinsho Shinkeigaku 2007; 47: 434-436.
16. Hiemstra HS, Schloot N, van Veelen P, et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci U S A 2001; 98: 3988-3991.
17. Matà S, Muscas G, Naldi I, et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 2008; 199: 155-159.
18. Schloot NC, Roep BO, Wegmann DR, et al. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Diabetologia 1997; 40: 332-338.
19. Kahara T, Takamura T, Otoda T, Ishikura K, Matsushita E. Transient anti-GAD antibody positivity and acute pancreatitis with pancreas tail swelling in a patient with susceptible haplotype for type I diabetes mellitus. Int Med 2009; 48: 1897-1899.
20. Iwaoka T. A case of fulminant type I diabetes with transiently positive anti-GAD antibodies. Endocr J 2003; 50: 225-231.
21. Piccolo G, Tavazzi E, Cavallaro T, et al. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J Neurol Sci 2010; 15: 148-149.
22. Nociti V, Frisullo G, Tartaglione T, et al. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol 2010; 17: e5.
23. Kanter I, Huttner HB, Staykov D, et al. Cyclophosfamide for antiGAD antibody positive refractory status epileptic. Epilepsia 2008; 49: 914-920.
24. Vulliemoz S, Vanini G, Truffert A, Chizzolini C, Seeck M. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2007; 78: 187-189.